{
    "nct_id": "NCT05405387",
    "official_title": "A Randomized Phase 2 Trial Investigating the Impact of Budesonide Prophylaxis on Incidence of ≥ Grade 2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant",
    "inclusion_criteria": "* Subject aged ≥ 18 years.\n* History of histologically confirmed multiple myeloma and/or Plasma Cell Leukemia diagnosis undergoing ASCT who are determined to be fit by the investigator to undergo ASCT with melphalan 200 mg/m2 or melphalan 140 mg/m2 as conditioning.\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n* Adequate organ function as defined as:\n\n  --Hepatic:\n  * Total Bilirubin ≤ 2 x institutional upper limit of normal (ULN).\n  * AST(SGOT)/ALT(SGPT) ≤ 5 × institutional ULN\n* For female subjects who have not undergone surgical sterilization: Negative pregnancy test or evidence of post-menopausal status. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n\n  * Women < 50 years of age:\n\n    * Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and\n    * Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution; or\n    * Underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n  * Women ≥ 50 years of age:\n\n    * Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or\n    * Had radiation-induced menopause with last menses >1 year ago; or\n    * Had chemotherapy-induced menopause with last menses >1 year ago; or\n    * Underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).\n\nInclusion Criteria required for Patients Enrolling in Safety Run-In Cohort only:\n\n-Patient must have at least 2.5 x 106 CD34 cells in reserve for use if engraftment is delayed\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Ongoing or current use of oral budesonide at the time of enrollment.\n* Receiving other investigational agents, unless deemed acceptable after consultation with the PI\n* Subjects with moderate or severe pre-existing hepatic impairment as classified according to the Child-Pugh system.\n* Prior history or current diagnosis of inflammatory bowel disease, microscopic colitis at baseline.\n* Prior history of receiving an allogenic stem cell transplant\n* Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study.\n* Known prior severe hypersensitivity to melphalan or budesonide or any component in their formulations or compounds of similar composition (NCI CTCAE v5.0 Grade ≥ 3).\n* Subjects taking prohibited medications as described in Section 6.6.1. A washout period of prohibited medications for a period of at least five half-lives or 14 days (whichever is shorter) should occur before the start of treatment.",
    "miscellaneous_criteria": ""
}